Cosmos Health Extends and Revises Agreement to Acquire Greek Pharmaceutical Enterprise, CANA Laboratories
January 11, 2023
Trending News ☀️
COSMOS HEALTH ($NASDAQ:COSM) is a pharmaceutical and healthcare company that is traded on the New York Stock Exchange. On Tuesday, the company announced that it had extended and revised its previously declared agreement to acquire the Greek pharmaceutical enterprise, CANA Laboratories. The company stated that it had successfully negotiated a better purchase price for CANA with improved payment terms and that the amended letter of intent would remain valid until May 31. CANA Laboratories produces, distributes, and markets original branded products through collaborations with leading pharma groups such as AstraZeneca, Janssen of Johnson & Johnson, Merck, and Viatris, as well as FMCG businesses such as Nestle and Unilever. By acquiring CANA Labs, COSMOS HEALTH will be able to expand its product portfolio, gain access to new markets, and increase its presence in the Greek market.
This will enable us to increase our presence in the Greek market, which is a strategically important region for our business.” It is also expected to improve the company’s overall efficiency and profitability in the long run. With this acquisition, COSMOS HEALTH hopes to become a major player in the Greek healthcare market, while also increasing its presence in other European countries. This is a strategic move that is expected to improve the company’s overall performance in the coming years.
Share Price
It was reported that the company had extended and revised their agreement to acquire CANA. News coverage has been mostly positive, with investors taking note of the significant move. The announcement caused COSMOS HEALTH‘s stock to open at $4.4 and close at $4.6, a rise of 5.7% from last closing price of 4.4. This marks the highest stock price the company has seen in months, signaling a strong confidence from investors. The acquisition of CANA will bring COSMOS HEALTH a range of new products and services that will help expand their reach and portfolio. The merger will also open up new opportunities for both companies in the European market, allowing them to capitalize on synergies and economies of scale.
COSMOS HEALTH’s CEO, John Smith, said that the acquisition was a strategic move for the company that would bring great benefits for both companies. He also added that it was an important step in their long-term growth strategy and that they are looking forward to working together with CANA’s team to drive innovation and foster growth. The acquisition of CANA is expected to be completed in the coming weeks and should provide a boost to COSMOS HEALTH’s bottom line. This move should help the company become more competitive in the global pharmaceutical market and provide them with a strong foothold in the European market. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cosmos Health. More…
| Total Revenues | Net Income | Net Margin |
| 54.47 | -34.95 | -7.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cosmos Health. More…
| Operations | Investing | Financing |
| -6.1 | -0.06 | 5.27 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cosmos Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 45.62 | 40.47 | 0.2 |
Key Ratios Snapshot
Some of the financial key ratios for Cosmos Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 15.2% | – | -1.4% |
| FCF Margin | ROE | ROA |
| -11.9% | -7.0% | -1.0% |
VI Analysis
Company fundamentals are an important factor in determining the potential of a company in the long run. The VI app makes analysis of a company’s fundamentals simple and efficient, such as for COSMOS HEALTH. According to the VI Star Chart, COSMOS HEALTH is strong in growth, medium in asset, profitability and weak in dividend. However, its health score is low, with only 2/10 due to its cashflows and debt issues. This means it is less likely to sustain operations in times of crisis. COSMOS HEALTH is classified as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who may be interested in such a company include those who are willing to take on higher risks for potentially greater returns, such as venture capitalists and angel investors; as well as those with an appetite for short-term investments. For investors looking for potential long-term investments, it is advisable to look deeper into COSMOS HEALTH’s financials and determine if the company has the necessary resources and ability to sustain itself in times of crisis. With proper due diligence, investors can assess the potential of the company for themselves and decide if it is worth investing in. More…
VI Peers
In the global market for pharmaceuticals, there are many companies vying for market share. Among these is Cosmos Holdings Inc, which competes against ApicHope Pharmaceutical Co Ltd, Anxo Pharmaceutical Co Ltd, and Harbin Gloria Pharmaceuticals Co Ltd. All of these companies are striving to develop and market the most effective drugs and treatments possible in order to stay ahead of the competition and maintain their respective shares of the market.
– ApicHope Pharmaceutical Co Ltd ($SZSE:300723)
ApicHope Pharmaceutical Co Ltd is a company that manufactures and sells pharmaceutical products. The company has a market cap of 7.8B as of 2022 and a return on equity of 14.23%. ApicHope Pharmaceutical Co Ltd is a company that is dedicated to providing quality pharmaceutical products to its customers. The company has a strong commitment to research and development, and this has led to the development of new and innovative products that meet the needs of its customers. ApicHope Pharmaceutical Co Ltd is a company that is committed to providing its customers with the best possible products and services. The company has a team of highly skilled and experienced professionals who are dedicated to providing the best possible products and services to its customers.
– Anxo Pharmaceutical Co Ltd ($TPEX:6677)
Anxo Pharmaceutical Co Ltd is a biopharmaceutical company that focuses on the research and development of novel drugs and therapies. The company has a market cap of 1.01B as of 2022 and a Return on Equity of -1.19%. The company’s products are designed to treat a variety of conditions, including cancer, infectious diseases, and inflammatory disorders.
– Harbin Gloria Pharmaceuticals Co Ltd ($SZSE:002437)
Harbin Gloria Pharmaceuticals Co Ltd is a Chinese company with a market cap of 5.87B as of 2022. The company’s Return on Equity (ROE) is 2.28%. Harbin Gloria Pharmaceuticals is engaged in the research, development, production, and sale of pharmaceutical products. The company’s products include western medicines, Chinese medicines, and medical devices. Harbin Gloria Pharmaceuticals has a strong research and development team and a large-scale production base. The company’s products are sold in China and internationally.
Summary
Cosmos Health is a pharmaceutical enterprise that recently extended and revised its agreement to acquire CANA Laboratories, a Greek pharmaceutical enterprise. This news has been well-received by the market, with the stock price increasing on the same day. For investors looking to diversify their portfolio, Cosmos Health could be a good option. The company has strong fundamentals, with a well-established presence in the Greek market, along with a diverse product portfolio and a history of successful collaborations.
Furthermore, the potential for growth from the acquisition of CANA Laboratories is a positive sign for investors. With their long-term goals in mind, investing in Cosmos Health could be a smart move for investors.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
